Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SESepterna Inc logo

Septerna Inc (SEPN)

NASDAQ · Currency in USD
$40.41 ▼ -0.47 (-1.15%)
At close: Oct 23, 4:00 PM ET. Market closed.
$40.41 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:44 PM ET

Summary

Previous Close
$40.88
Open
$40.37
Day's Range
$39.86 – $41.06
52 Week Range
$17.55 – $51.10
Volume
200,306
Avg. Volume
426,680
Market Cap
$1.89B
Beta (5Y Monthly)
2.28
PE Ratio (TTM)
--
EPS (TTM)
-$0.54
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$50.40

Profile: Septerna Inc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
123
CEO
Jeffrey T. Finer

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.42 · Revenue est. $20.78M
DateEst.Actual
Aug 10, 2026-$0.43-$0.29Beat
May 12, 2026-$0.51-$0.19Beat
Mar 9, 2026-$0.23-$0.24Miss
Nov 10, 2025$0.19-$0.09Miss
Aug 11, 2025-$0.05-$0.56Miss
May 15, 2025-$0.38-$0.49Miss

Analyst view

Consensus price target
$50.40 ▲ +24.7%
Range $43.00 – $60.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on SEPN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.